Key result
Troponin testing during inpatient admission was associated with significantly higher odds of death during hospitalization (OR 3.11; 95% CI 2.63-3.71; p<0.0001).
Why the study?
Large numbers of hospitalized patients undergo troponin I testing when acute myocardial infarction is unlikely or unexpected.
Does troponin testing associate with mortality in hospitalized patients?
Cohort (n=54,039)
Yes
Does troponin testing associate with mortality in hospitalized patients?
Troponin testing and elevated troponin levels are strongly associated with in-hospital mortality, reflecting selection bias where sicker patients are more likely to be tested.
May reflect selection of sicker patients rather than causal harm; leaves open effects of testing on outcomes in unselected inpatients.
Introduction: Troponin I (TnI) is a principal biomarker in diagnosing acute myocardial infarction (AMI). However, large numbers of hospitalized patients are tested for TnI in whom AMI is unlikely or not expected. Hypothesis: We hypothesized the baseline comorbidities of those undergoing troponin testing differ from those not tested and that troponin testing is associated with outcomes. Methods: In total, 54,039 inpatient admissions from a 9-hospital system in Texas were reviewed over a 24-month period (2017-2018). Data were collected on primary international classification of disease (ICD-10) diagnoses, TnI, risk factors, and death during hospitalization or readmission within 30 days. Odds ratios were calculated for all patients adjusted for demographic differences in the population. Bivariate analysis was performed on the baseline risk factors for both troponin testing and troponin positivity. Results: TnI testing occurred in 30,173/54,039 (55.8%) individual hospital admissions. Of those, 19.9% had at least one elevated TnI value >99th% (0.1 ng/ml). Tested patients were older (70.1 [IQR 59.5, 80.9] vs 63.7 [IQR 53.4, 73.1] years), more likely to be male (14,497/30,173 (48.1%) vs 10,845/23,866 (45.4%)) and had a greater burden of cardiovascular disease and risk factors including: gender, race, smoking, hypertension, hyperlipidemia, type 2 diabetes mellitus, coronary artery disease, chronic kidney disease, chronic obstructive pulmonary disease, prior cerebrovascular accident, and prior AMI. Troponin testing was associated with death during hospitalization (OR 3.11, 95% CI 2.63, 3.71, p<0.0001), and an elevated troponin was found to be associated with mortality (OR 4.06, 95% CI 3.49, 4.72, p<0.0001). Conclusions: Troponin testing is associated with death during index hospitalization. Troponin values >99th% were associated only with increased mortality. This data suggest that selection plays a role in identifying patients at risk for in-hospital death.
No takes yet. Share an insight, caveat, or question.
Escobedo et al. (2020) conducted a cohort in Inpatient admissions (n=54,039). Troponin testing vs. No troponin testing was evaluated on Death during hospitalization (OR 3.11, 95% CI 2.63-3.71, p=<0.0001). Troponin testing during inpatient admission was associated with significantly higher odds of death during hospitalization (OR 3.11; 95% CI 2.63-3.71; p<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: